Evotec stock softens as Project Horizon funding highlights Q2 2026 pressure

Evotec SE stock (ISIN DE0005664809) is under pressure on August 24, 2026, with shares slipping in Xetra trading while investors digest weaker second-quarter 2026 earnings and a €116.1 million convertible bond that finances the company’s Project Horizon transformation program.

Per same-day market coverage dated August 24, 2026, Evotec shares in the Xetra session were quoted at €3.28 at 4:28 p.m. local time, representing a decline of 2.1 percent versus the prior close and reinforcing the low single-digit euro range that has characterized trading in late August 2026.

In late August 2026, editorial analysis of Evotec’s latest numbers points to revenue and net income declines in the second quarter of 2026 compared with the prior-year period, framing the convertible bond issuance as a move to strengthen the balance sheet while management continues to invest in long-term pipeline and platform initiatives.

Q2 2026 numbers underline earnings headwinds

An earnings commentary published on August 22, 2026, reflects that Evotec’s most recent reported quarterly results for the second quarter of 2026 showed a decline in revenue relative to the same quarter in 2025, highlighting pressure on the top line as the company navigates a transition period. The Q2 2026 analysis links that weaker revenue performance directly to the need for careful cost management and targeted investment in core strategic programs.

The same Q2 2026 earnings discussion indicates that net income softened compared with the prior-year quarter, underscoring how operational challenges and the costs associated with implementing Project Horizon weighed on Evotec’s bottom line. By describing both revenue and net income as lower in Q2 2026 versus Q2 2025, the commentary provides a quantified comparison that signals the degree of near-term earnings strain while management pursues longer-term growth objectives.

Within this Q2 2026 framework, investors are encouraged to watch not just the absolute level of revenue and profit, but also the pace of change from quarter to quarter and year over year, since the combination of declining sales and weaker net income relative to the prior-year period helps explain why the company has opted for a convertible bond to reinforce its capital structure.

Convertible bond funds Project Horizon and reshapes capital structure

The late-August 2026 coverage emphasizes that Evotec raised €116.1 million through a convertible bond issued in August 2026, with the proceeds earmarked to support Project Horizon, a transformation program designed to sharpen the focus on key discovery and development platforms. The convertible bond report describes this financing as part of a broader effort to improve balance-sheet flexibility while funding R&D commitments.

According to the same late August 2026 context, Evotec shares have been trading in the low single-digit euro range on European trading venues, with recent quotes a little above €5 on August 22, 2026 before sliding closer to €3.28 on August 24, 2026, illustrating how the stock’s equity value now stands at a fraction of earlier valuations when investors assigned higher multiples to the company’s pipeline and platform potential.

The link between the €116.1 million convertible bond size and Evotec’s current market capitalization is central for investors assessing dilution risk and leverage. As of late August 2026, the commentary suggests that the convertible amount should be viewed against a market value anchored by low single-digit share prices, implying that the bond represents a meaningful but not overwhelming component of the company’s capital structure, especially if Project Horizon can stabilize revenue trends after the Q2 2026 decline relative to 2025.

Late-August 2026 trading range and sentiment reset

Market data snapshots incorporated in the late-August 2026 analysis show Evotec shares quoted in the low single digits on European exchanges, with indicated levels a little above €5 on August 22, 2026 before settling near €3.28 in Xetra trading on August 24, 2026. Intraday price reporting for August 24, 2026 cites the 2.1 percent decline to €3.28 as of 4:28 p.m., while coverage earlier in the day referred to modest losses at €3.32 and €3.33, framing the session as a gradual softening rather than a sharp dislocation.

The same price commentary for August 24, 2026 documents that Evotec stock opened the Xetra session at €3.33 and traded at €3.32 at 12:28 p.m., with a 1.1 percent decline at that point, before extending the move to a 2.1 percent drop at €3.28 later in the afternoon. Those intraday changes offer a concrete comparison for investors tracking momentum, showing a progression from a roughly one-percent loss mid-session to a more pronounced decline by late trading.

Against the backdrop of the Q2 2026 revenue and net income declines versus the prior-year quarter and the August 2026 convertible bond issuance, this trading pattern suggests that sentiment has reset, with investors now pricing the stock firmly in the low single-digit euro range. The difference between the quote a little above €5 on August 22, 2026 and the €3.28 level on August 24, 2026 underscores how quickly the market can adjust expectations in response to earnings pressure and capital-structure changes.

Evotec’s discovery and development platform business

Evotec SE operates as a drug discovery and development company, providing research platforms and services that help pharmaceutical and biotechnology partners advance new therapies from early discovery stages through preclinical and clinical development. Its business model centers on leveraging proprietary technologies and expertise across multiple disease areas, with revenue streams that combine service fees, milestones, and potential royalties tied to successful partner programs.

Within Project Horizon, Evotec is focusing on strengthening its core platforms and aligning resources with areas where it believes its discovery capabilities and integrated R&D model can deliver the most value for partners and patients. The emphasis on platform efficiency and strategic prioritization aims to counteract the revenue decline observed in Q2 2026 relative to the prior-year quarter by increasing throughput, improving margins, and deepening long-term partnerships.

Because the Q2 2026 commentary highlights the tension between funding long-term pipeline work and absorbing near-term earnings pressure, investors will be watching how Evotec balances the service-based nature of its business with the inherent variability of milestone and royalty income. The success of Project Horizon in stabilizing and ultimately growing revenue after the Q2 2026 dip versus 2025 will be a key indicator of whether the current financing and transformation efforts can translate into a stronger earnings profile.

Evotec stock level as of the latest Xetra session

As of August 24, 2026, intraday data from the Xetra exchange show Evotec shares trading at €3.28 in the afternoon session, down 2.1 percent from the previous close, with earlier prints at €3.32 and €3.33 during the same day’s trading hours.

This low single-digit euro price zone, combined with the Q2 2026 revenue and net income declines versus the prior-year quarter and the €116.1 million convertible bond supporting Project Horizon, defines the current context in which investors are evaluating Evotec’s risk and potential.

Read more

More on Evotec stock and Project Horizon financing

Fact box

Company: Evotec SE

ISIN: DE0005664809

Ticker: EVT

Exchange: Xetra

Price (as of August 24, 2026, 4:28 p.m. local time): €3.28

Sector / Industry: Health care / Biotechnology and drug discovery services

Index membership: TecDAX